In pulmonary function testing for asthma assessment, which result indicates reversible airway disease?

Prepare for the NATA Position Statements Test with customized quiz materials. Study with flashcards, multiple choice questions, and detailed explanations. Elevate your readiness for the examination!

Multiple Choice

In pulmonary function testing for asthma assessment, which result indicates reversible airway disease?

Explanation:
Reversibility of airway obstruction after bronchodilator is what indicates asthma in pulmonary function testing. FEV1 is the amount of air you force out in one second, and a true reversible obstruction will show a meaningful rise after a bronchodilator is given. The commonly used threshold is an increase of 12% or more in FEV1, usually with an absolute gain around 200 mL in adults, which shows the airwaysRespond to medication and are not permanently narrowed—classically seen in asthma. If FEV1 decreases after bronchodilator, or if there is no meaningful change, this argues against reversible airway disease and suggests non-reversible obstruction or another pattern. A large increase in FEV1 without bronchodilator isn’t a test of reversibility, since reversibility is assessed specifically with the bronchodilator challenge.

Reversibility of airway obstruction after bronchodilator is what indicates asthma in pulmonary function testing. FEV1 is the amount of air you force out in one second, and a true reversible obstruction will show a meaningful rise after a bronchodilator is given. The commonly used threshold is an increase of 12% or more in FEV1, usually with an absolute gain around 200 mL in adults, which shows the airwaysRespond to medication and are not permanently narrowed—classically seen in asthma.

If FEV1 decreases after bronchodilator, or if there is no meaningful change, this argues against reversible airway disease and suggests non-reversible obstruction or another pattern. A large increase in FEV1 without bronchodilator isn’t a test of reversibility, since reversibility is assessed specifically with the bronchodilator challenge.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy